News | October 21, 2022
Aarti Drugs Q2 FY23 revenue up 19%; Profit down 5.6%
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Proceeds from the proposed issue will be utilized to part finance Balaxi’s planned EU GMP-compliant manufacturing facility for Oral Solid Dosages and Liquid Injectables at TSIIC Pharma Formulations SEZ
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
The existing hospital premises has the scope to further scale up the bed capacity as and when required in the future with minimal Capex.
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The plant is expected to start commercial operations from Q4FY24
Subscribe To Our Newsletter & Stay Updated
